Related Experiment Videos
Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
1Donald W. Reynolds Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock 72205, USA. swbarger@life.uams.edu
Nature
|August 28, 1997
Summary
Secreted beta-amyloid precursor protein derivatives (sAPP) can activate brain microglia, potentially contributing to Alzheimer's disease. Apolipoprotein E3, but not E4, blocks this activation, suggesting a role in disease risk.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Genetics indicate a role for beta-amyloid precursor protein (beta-APP) in Alzheimer's disease (AD) pathogenesis.
- Elevated beta-APP levels are linked to increased AD risk and Alzheimer's-like pathology.
- Inflammatory processes are also implicated as contributors to AD development.
Purpose of the Study:
- To investigate if secreted beta-APP derivatives, specifically sAPP-alpha, can trigger inflammatory responses in microglia.
- To determine the differential effects of sAPP-alpha and sAPP-beta on microglial activation and neurotoxicity.
- To examine the influence of apolipoprotein E variants (ApoE3 and ApoE4) on sAPP-alpha-induced microglial activation.
Main Methods:
- Treatment of microglia with recombinant sAPP-alpha and sAPP-beta.
- Assessment of microglial activation markers.
- Measurement of neurotoxin production by activated microglia.
- Incubation of sAPP-alpha with apolipoprotein E3 (ApoE3) and apolipoprotein E4 (ApoE4) prior to microglial treatment.
Main Results:
- sAPP-alpha treatment significantly increased microglial activation markers.
- sAPP-alpha enhanced the production of neurotoxins by microglia.
- Apolipoprotein E3, but not ApoE4, effectively blocked sAPP-alpha-induced microglial activation.
- sAPP-beta, a product of amyloidogenic processing, also activated microglia.
Conclusions:
- Secreted beta-APP derivatives, including sAPP-alpha and sAPP-beta, can activate microglia, suggesting a role in AD-related neuroinflammation.
- The differential effect of ApoE3 versus ApoE4 in blocking sAPP-alpha activation highlights a potential mechanism for ApoE's influence on AD risk.
- Increased amyloidogenic processing, leading to higher sAPP-beta levels and potentially altered sAPP-alpha activity, may disrupt the balance of sAPP-mediated neuroprotection and neuroinflammation in AD.